Skip to main content

More Than a Sneaker: Nike Moment Shines Spotlight on the Foundation's Work

More Than a Sneaker: Nike Moment Shines Spotlight on the Foundation's Work

Yesterday, Nike and The Michael J. Fox Foundation (MJFF) launched the Nike Draw -- a weeklong online draw to win a pair of the iconic Nike Mag shoe. The 2016 Nike Mag, unlike its 2011 prototype predecessor, features innovative self-lacing technology, first seen as a vision of the future on the silver screen by Michael J. Fox decades ago.

Thanks to Nike, 100 percent of proceeds from the Draw will support the high-impact programs of the Foundation. For just $10 per ticket (with no limit to the number of tickets purchased!) sneakerheads, movie buffs and the Parkinson's community can unite in pursuit of a cure and a piece of pop culture history.

As the Draw kicked off, Matt Herper of Forbes spoke with Michael J. Fox to discuss how the Foundation is leading its own kind of innovation in Parkinson's research.

What Fox has become a master at, though, is leveraging his decades of fame, particularly his iconic turns as the "it" star of the early eighties, into a disease foundation that raised and spent $87 million last year and has turned Parkinson's research from a pharma backwater to a hot area.

Much like the Draw's ability to unite millions of fans looking to win a pair of the coveted shoes, the Foundation, too, is engaging thousands of patients and their families to take action and speed research toward a cure:

Another big area: using the Fox brand name to get patients to sign up for clinical trials. A pilot recruitment strategy using Facebook ads lowered the cost of recruiting a patient to less than $24, compared to more than $200 using traditional routes like events, ads and newspapers. The company's clinical trial search engine, Fox Trial Finder, has sped up the development of many Parkinson's drugs, including Acadia Pharmaceuticals' Nuplazid, the first drug to treat Parkinson's psychosis, and an experimental drug to treat Parkinson's movement disorders from Adamas Pharmaceuticals that will be filed with the FDA this year.

Read the full story on

And earlier today, Michael visited "Good Morning America" to talk with host and MJFF Board member George Stephanopoulos about what this moment means for the Foundation and the progress we're seeing in genetics and wearable technology to track disease progression.

Be part of this moment and help the Foundation's work to speed new treatments for patients by entering the Draw at

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.